期刊文献+

Zebularine调控卵巢癌细胞hMLH1基因再表达 被引量:2

Zebularine Induces Demethylation and Re-expression of hMLH1 Gene in Human Ovarian Cancer Cell Line
下载PDF
导出
摘要 目的探讨去甲基化药物Zebularin(eZeb)对体外培养的顺铂耐药的卵巢癌细胞A2780/cp70hMLH1基因甲基化状态的影响及表达调控作用。方法应用不同浓度的Zeb(50μmol/L,100μmol/L,200μmol/L)处理体外培养的卵巢癌细胞A2780/cp70后,甲基化特异性PCR(Methylation-specific PCR,MSP)法检测用药前后细胞中hMLH1基因的甲基化状态,RT-PCR法及Western-blot法检测用药前后细胞中hMLH1基因mRNA及蛋白表达的变化。结果 hMLH1基因在卵巢癌细胞A2780/cp70中呈异常甲基化状态,在mRNA及蛋白水平表达阴性。经过Zeb处理后,hMLH1基因呈去甲基化状态,其mRNA及蛋白重新表达。结论异常甲基化是卵巢癌细胞A2780/cp70hMLH1基因失活的原因,去甲基化药物Zeb能使hMLH1基因去甲基化从而调控其重新表达。 Objective To investigate the effect of demethylation agent zebularine(Zeb) on methylation state and expression of hMLH1 gene in human cisplatin-resistant ovarian cancer cell line A2780/cp70.Methods A2780/cp70 cells were cultured in RPMI 1640 and were treated with different concentrations (50 μmol/L,100 μmol/L,200 μmol/L) of DNA methyl-transferase inhibitor Zeb.Methylation-specific PCR (MSP) was used to detect methylation state of hMLH1 gene.RT-PCR and Western blot were used to detect expression of mRNA and protein of hMLH1 gene before and after treatment with Zeb respectively.Results Promoter hypermethylation of hMLH1 gene was detected in ovarian cancer cell A2780/cp70,and no expression was detected before treatment.After treated with Zeb,hMLH1 gene exhibited demethylation and its expression occured at mRNA and protein level.Conclusion Zeb can induce demethylation of hMLH1 gene and regulate its re-expression.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2011年第7期597-599,604,共4页 Journal of China Medical University
基金 辽宁省教育厅高校科研计划(2008839) 辽宁省自然科学基金(20092116)
关键词 ZEBULARINE HMLH1基因 卵巢癌 DNA甲基化 zebularine hMLH1 gene ovarian cancer DNA methylation
  • 相关文献

参考文献10

  • 1Plasencial CP,Gonzalez AD.Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy [ J ]. Mol Cancer, 2006,5 ( 1 ) : 27-36.
  • 2Makarla PB, Saboorian MH, Ashfaq R, et al.Promoter hypermethyla- tion profile of ovarian epithelial neoplasms [J].Clin Cancer Res, 2005,11 ( 15 ) : 5365-5369.
  • 3Gifford G, Paul J, Vasey PA, et al.The acquisition of hMLH1 methyla- tion in plasma DNA afler chemotherapy predicts poor suJwival for o- varian cancer patients[J ]. Clin Cancer Res, 2004, 10(13) :4420-4426.
  • 4Yoo CB, Cheng JC,Jonesl PA.Zebularine : a new drug for epigenetic therapy[ J ]. B ioch Soc Trans, 2004,32(6 ) :910-912.
  • 5Baylin SB.Reversal of gene silencing as a therapeutic target for can- cer roles for DNA methylation and its interdigitation with chromatin[J].Novattis Found Symp,2004,259( 1 ):226-233.
  • 6沈文静,戴冬秋,郭科军,李雪梅.上皮性卵巢癌组织中RASSF1A和BRCA1及P16基因异常甲基化检测及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(7):530-533. 被引量:6
  • 7Worm J, Guldberg P.DNA methylation:an epigenetie pathway to can- cer and a promising target for anticancer therapy [J].Oral Pathol Med,2002,31 (8) : 443-449.
  • 8Aparicio A,Weber JS.Review of the clinical experience with 5-aza- cytidine and 5-aza-2'-deoxycytidine in solid tumors [J].Curr Opin Investig Drugs, 2002,3 (4) : 627-633.
  • 9Cheng JG, YO0 CB, Weisenberger DJ, et a l.Preferential response of cancer cells to zebularine [ J ].Caneer Cell, 2004,6( 2 ) : 151-158.
  • 10Cheng JC, Matsen CB, Gonzalesfa, el al.lnhibition of DN A methyla- tion and reactivation of sileneed genes by zebularlne[J ].J Natl Can- cer Inst, 2003,95( 5 ) : 399-409.

二级参考文献10

  • 1沈文静,戴冬秋.卵巢癌表遗传学研究进展[J].中华肿瘤防治杂志,2007,14(10):790-794. 被引量:11
  • 2Ducasse M,Brown M A.Epigenetic aberrations and cancer[J].Mol Cancer,2006,5(1):60-75.
  • 3Herman J G,Graff J R,Myohanen S,et al.Methylation-specific PCP:A novel PCP assay for methylation status of CpG islands[J].Proc Natl Acad Sci U S A,1996,93(18):9821-9826.
  • 4Makarla P B,Saboorian M H,Ashfaq R,et al.Promoter hypermethylation profile of ovarian epithelial neoplasms[J].Clin Cancer Res,2005,11(15):5365-5369.
  • 5Agathanggelou A,Cooper W N,Latif F.Role of the Ras-association domain family 1 tumor suppressor gene in human cancers[J].Cancer Res,2005,65(9):497-508.
  • 6Ibanez de Caceres I,Battagli C,Esteller M,et al.Tumor cell-speeific BRCA1 and RASSF1A hypermethylation in serum,plasma,and peritoneal fluid from ovarian cancer patients[J].Cancer Res,2004,64(18):6476-6481.
  • 7Esteller M,Silva J M,Dominguez G,et al.Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors[J].J Natl Cancer Inst,2000,92(7):564-569.
  • 8Yang H J,Liu V W,Wang Y,et al.Differential DNA methylation profiles in gynecological cancers and correlation with clinicopathological data[J].BMC Cancer,2006,6(2):212-224.
  • 9Dulaimi E,Ibanez de Caceres I,Uzzo R G,et al.Promoter hypermethylation profile of kidney cancer[J].Clin Cancer Res,2004,10(12):3972-3979.
  • 10Gerdes B,Ramaswamy A,Ziegler A,et al.p16INK4ais a prognostic marker in resected ductal pancreatic cancer,an analysis of p16mINK4a,p53,MDM2,and Rb[J].Ann Surg,2002,235(1):51-59.

共引文献5

同被引文献25

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research [ J ]. Br J Cancer, 2012, 106(2) : 248-253.
  • 3Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy [J]. Biochera Soc Trans, 2004, 32(Pt 6) : 910-912.
  • 4Jeong P, Min BD, Ha YS, et al. RUNX3 methylation in normal sur- rounding urothelium of patients with non-muscle-invasive bladder canc- er: potential role in the prediction of tumor progression [J]. Eur J Surg Oncol, 2012, 38( 11 ) : 1095-1100.
  • 5Shiraha H, Nishina S, Yamameto K. Loss of runt-related transcription fac- tor 3 causes development and progression of hepatocellular carcinoma [ J ]. J Cell Biochem, 2011, 112(3): 745-749.
  • 6Lee CW, ho K, ho Y. Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer [ J]. Cancer Res, 2010, 70(10) : 4243-4252.
  • 7Kodach LL, Jacobs RJ, Heijmans J, et al. The role of EZH2 and DNA methylation in the silencing of the tumor suppressor RUbX3 in colorec- tal cancer[ J]. Carcinogenesis, 2010, 31 (9) : 1567-1575.
  • 8Calone I, Souchelnytskyi S. Inhibition of TGFI3 signaling and its impli- cations in anticancer treatments [ J]. Exp Oncol, 2012, 34 ( 1 ) : 9-16.
  • 9Liu LC, Tsao TC, Hsu SR, et al. EGCG inhibits transforming growth factor-I-mediated epithelial-to-mesenchymal transition via the inhibi- tion of Smad2 and Erkl/2 signaling pathways in nonsmall cell lung cancer cells [J]. J Agric Food Chem, 2012, 60(39) : 9863-9873.
  • 10Watanabe K, Sugai M, Nambu Y, et al. Requirement for Runx pro- teins in IgA class switching acting downstream of TGF-beta 1 and reti- noic acid signaling [J]. J Immunol, 2010, 184(6) : 2785-2792.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部